

Catalog# BP-50545

Daratumumab Biosimilar, CD38 Monoclonal Antibody

Daratumumab Biosimilar uses the same protein sequences as the therapeutic antibody daratumumab.

Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody. Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition.

Product Details	
CAS No.	945721-28-8
Species Reactivity	Human
Source	Daratumumab biosimilar CHO stable cell line
Isotype	Human IgG1 kappa
Class	Monoclonal
Type	Antibody
Clone	Daratumumab Biosimilar
Conjugate	Unconjugated
Immunogen	Human CD38 protein, causing cells to apoptosis via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, inhibition of mitochondrial transfer or antibody-dependent cellular phagocytosis
Purity	>95%
Molecular Weight	145.26 kDa
Protein Concentration	1 mg/ml
Formulation	0.2 µM filtered PBS solution, pH 6.0
Storage conditions	4°C for short time, -20°C or -80°C for long time.